Login / Signup

An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials.

Paul JankThomas KarnMarion T van MackelenberghJudith LindnerDenise TreueJens HuoberKnut EngelsChristine SolbachKurt DieboldFrederic MarméVolkmar MuellerAndreas SchneeweißHans-Peter SinnTanja FehmChristian SchemElmar StickelerPeter Andreas FaschingJan BudcziesBärbel FelderValentina NekljudovaJohannes HoltschmidtMichael UntchCarsten DenkertSibylle Loibl
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
The PIK3CA hotspot mutation p.H1047R is associated with worse pCR rates following NACT in HER2pos breast cancer, whereas hotspot mutations in exon 9 seem to have less impact.
Keyphrases
  • clinical trial
  • rectal cancer
  • lymph node
  • protein kinase
  • stem cells
  • squamous cell carcinoma
  • open label
  • study protocol
  • cell therapy
  • placebo controlled